Cancer‐associated fibroblasts potentiate colorectal cancer progression by crosstalk of the IGF2–IGF1R and Hippo–YAP1 signaling pathways
- 17 December 2022
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 259 (2) , 205-219
Abstract
Colorectal cancer (CRC) is one of the most common cancers worldwide. The tumor microenvironment exerts crucial effects in driving CRC progression. Cancer‐associated fibroblasts (CAFs) serve as one of the most important tumor microenvironment components promoting CRC progression. This study aimed to elucidate the novel molecular mechanisms of CAF‐secreted insulin‐like growth factor (IGF) 2 in colorectal carcinogenesis. Our results indicated that IGF2 was a prominent factor upregulated in CAFs compared with normal fibroblasts. CAF‐derived conditioned media (CM) promoted tumor growth, migration, and invasion of HCT 116 and DLD‐1 cells. IGF1R expression is significantly increased in CRC, serving as a potent receptor in response to IGF2 stimulation and predicting unfavorable outcomes for CRC patients. Apart from the PI3K–AKT pathway, RNA‐seq analysis revealed that the YAP1‐target signature serves as a prominent downstream effector to mediate the oncogenic signaling of IGF2–IGF1R. By single‐cell RNA sequencing (scRNA‐seq) and immunohistochemical validation, IGF2 was found to be predominantly secreted by CAFs, whereas IGF1R was expressed mainly by cancer cells. IGF2 triggers the nuclear accumulation of YAP1 and upregulates YAP1 target signatures; however, these effects were abolished by either IGF1R knockdown or inhibition with picropodophyllin (PPP), an IGF1R inhibitor. Using CRC organoid and in vivo studies, we found that cotargeting IGF1R and YAP1 with PPP and verteporfin (VP), a YAP1 inhibitor, enhanced antitumor effects compared with PPP treatment alone. In conclusion, this study revealed a novel molecular mechanism by which CAFs promote CRC progression. The findings highlight the translational potential of the IGF2–IGF1R–YAP1 axis as a prognostic biomarker and therapeutic target for CRC. © 2022 The Pathological Society of Great Britain and Ireland.Keywords
Funding Information
- National Natural Science Foundation of China (81871900, 81903019, 82272990)
- Research Grants Council, University Grants Committee (CUHK 14100019, CUHK 14118518)
This publication has 40 references indexed in Scilit:
- Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer ModelsClinical Cancer Research, 2013
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal CancerNew England Journal of Medicine, 2013
- Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancerCellular Oncology, 2013
- Clinical and prognostic significance of Yes-associated protein in colorectal cancerTumor Biology, 2013
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- Correlation between Gene Expression of IGF-1R Pathway Markers and Cetuximab Benefit in Metastatic Colorectal CancerClinical Cancer Research, 2012
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisThe Lancet Oncology, 2010
- Relationships of Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor Expression to Clinical Outcomes in Patients with Colorectal CancerOncology, 2008
- Genetically Engineered Models Have Advantages over Xenografts for Preclinical StudiesCancer Research, 2006
- Gastric cancer: the role of insulin‐like growth factor 2 (IGF 2) and its receptors (IGF 1R and M6‐P/IGF 2R)The Journal of Pathology, 2003